Welcome to our dedicated page for CARLSMED SEC filings (Ticker: CARL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Carlsmed, Inc. filings document the regulatory record of a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions. Recent 8-K filings report results of operations and financial condition, including furnished earnings releases tied to the company’s aprevo® platform, product activity and revenue outlook.
The company’s SEC materials also cover emerging growth company status, annual meeting and proxy governance matters, and capital-structure disclosures. Material-event filings include amendments to loan and security arrangements, credit facility terms, warrant-related disclosures and other financing matters relevant to Carlsmed’s public-company reporting.
CARLSMED, INC. director Kevin C. O’Boyle received a grant of 13,698 shares of Common Stock as a stock award with no cash price per share. Following this grant, he directly holds 31,031 common shares. The award is structured as restricted stock units that each convert into one share upon vesting. These RSUs vest in full on the earlier of the day before Carlsmed’s 2027 annual meeting of stockholders or June 3, 2027, contingent on his continued service on the Board of Directors through that date.
Sidow Kevin reported acquisition or exercise transactions in this Form 4 filing.
CARLSMED, INC. director Kevin Sidow reported receiving an equity award in the form of 13,698 restricted stock units, each convertible into one share of Common Stock upon vesting. These RSUs vest in full on the earlier of the day before the company’s 2027 annual stockholder meeting or June 3, 2027, if he continues serving on the Board through that date. Following this grant, Sidow directly holds 73,264 shares of Common Stock, reflecting a routine, compensation-related increase in his equity stake.
ROOT JONATHAN D reported acquisition or exercise transactions in this Form 4 filing.
CARLSMED, INC. director Jonathan D. Root reported a compensation-related equity award and his updated shareholdings. He received a grant of 13,698 restricted stock units (RSUs), each convertible into one share of common stock upon vesting. These RSUs vest in full on the earlier of the day before the company’s 2027 annual stockholders meeting or June 3, 2027, if he continues serving on the Board through that date.
After this award, Root directly holds 497,697 shares of common stock. The filing also lists additional shares held indirectly through U.S. Venture Partners entities, where Root is a managing member and may be deemed to share voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.
CARLSMED, INC. director Philip M. Young received a grant of 13,698 restricted stock units (RSUs) of Common Stock on June 3, 2026. Each RSU converts into one share when it vests.
The RSUs vest in full on the earlier of the day before Carlsmed’s 2027 annual stockholder meeting or June 3, 2027, as long as Young continues serving on the board through that date. Following this award, he holds 31,031 shares directly, 53,333 shares indirectly through PMY Partners L.P., where he is sole general partner with voting and dispositive power, and additional shares through the Young Family Trust, where he is a trustee with similar authority.
Carlsmed, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, where stockholders voted on director elections and auditor ratification. Niall Casey and Philip Young were elected as Class I directors to serve until the 2029 annual meeting or until successors are elected and qualified.
Casey received 19,627,716 votes for and 1,352,117 votes withheld, while Young received 19,510,686 votes for and 1,469,147 votes withheld, with 4,628,080 broker non-votes on each director proposal. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,571,065 votes for, 5,858 against, and 30,990 abstentions.
Carlsmed, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $16.1 million from $10.2 million a year earlier, driven by higher procedure volumes for its AI-enabled aprevo spine surgery platform. Gross margin improved to 77.1%, reflecting lower per-unit production costs.
The company recorded a net loss of $8.7 million, deeper than the $5.7 million loss in the prior-year quarter, as it increased spending on research, sales, and public-company infrastructure. Operating activities used $13.0 million of cash. Carlsmed ended the quarter with $97.1 million in cash, cash equivalents, restricted cash, and short-term investments and $15.6 million of term-loan debt, which management believes is sufficient to fund operations for at least 12 months.
Carlsmed, Inc. reported strong first quarter 2026 results, with revenue of $16.1 million, up 58.2% from $10.2 million a year earlier. Gross profit rose to $12.4 million and gross margin improved to 77.1% from 74.9%.
The company posted a net loss of $8.7 million and adjusted EBITDA of -$7.5 million, both larger losses than in 2025 as it increased spending on research and development, sales and marketing, and general and administrative activities. Cash, restricted cash, and short-term investments totaled $97.1 million as of March 31, 2026.
Carlsmed raised its full-year 2026 revenue outlook to $72–$77 million, implying about 48% growth at the midpoint over 2025. The company highlighted new clinical data showing reduced revision surgeries for its aprevo personalized implants and initial procedures with its corra personalized fixation portfolio.
Carlsmed, Inc. is asking stockholders to vote at its 2026 annual meeting on electing two Class I directors for terms through 2029 and ratifying Ernst & Young LLP as independent registered public accounting firm for 2026.
The meeting is scheduled for June 3, 2026, at 8:00 a.m. Pacific time in San Diego, with an April 8, 2026 record date covering 27,232,278 outstanding common shares. A quorum requires a majority of voting power, and directors are elected by plurality, while auditor ratification needs majority support of shares present and entitled to vote.
The proxy describes Carlsmed’s classified seven-member board, committee structures, and governance policies including a clawback policy and insider trading restrictions. It also details director and executive pay, including 2025 cash bonuses tied to company performance and equity grants such as options and performance-based RSUs for the CEO, and shows that two venture-affiliated groups together beneficially own over half of the common stock.
Carlsmed, Inc. CEO and President Michael Cordonnier reported several stock option exercises and related share sales. On March 2 and 3, 2026, he exercised options for multiple blocks of common stock at exercise prices of $0.335 and $4.352 per share. He then sold 197,855 common shares at a weighted average price of $13.292 per share to cover the option exercise costs, withholding taxes, and associated broker fees under a broker-assisted cashless exercise.